Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
Seeking Alpha
|
May 16, 2023
X min read
Seeking Alpha
|
May 16, 2023
Share on Social
More like this
Media
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
Press
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
September 2, 2026
Read Now
